{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T00:05:21Z","timestamp":1793232321711,"version":"4.5.0"},"reference-count":67,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,7,8]],"date-time":"2025-07-08T00:00:00Z","timestamp":1751932800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Potassium competitive acid blockers (P-CABs) are a new class of acid suppressants that provide rapid and sustained inhibition of gastric acid secretion. Understanding the pharmacokinetic (PK) characteristics of P-CABs in various therapeutic uses is essential for optimizing treatment. This study aims to investigate the PK properties of P-CABs, focusing on drug interactions, food effects, and formulation impacts on their exposure and bioavailability.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We systematically searched MEDLINE and Embase up to July 2024. The search terms included \u201cPotassium competitive acid blockers\u201d or \u201cP-CABs\u201d or \u201crevaprazan\u201d or \u201cvonoprazan\u201d or \u201ctegoprazan\u201d or \u201cfexuprazan\u201d or \u201ckeverprazan\u201d or \u201czastaprazan\u201d and \u201cpharmacokinetics\u201d.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 37 studies were included. Meta-analysis and qualitative studies indicated that clarithromycin significantly increased vonoprazan and tegoprazan exposure [geometric mean ratio (GMR) (90% confidence interval (CI))] of AUC and Cmax: 1.565 (1.443, 1.687) and 1.538 (1.454, 1.621) for vonoprazan, 2.624 (2.513, 2.735) and 1.876 (1.771, 1.981) for tegoprazan, respectively. Vonoprazan had more of an inhibitory effect on cytochrome P450 (CYP) 3A and CYP2C19 compared to tegoprazan. P-CABs showed minimal interactions with nonsteroidal anti-inflammatory drugs or aspirin and were largely unaffected by food intake, except keverprazan and zastaprazan, which showed increased exposure.<\/jats:p><\/jats:sec><jats:sec><jats:title>Discussion<\/jats:title><jats:p>It is important to select the appropriate P-CABs by considering the degree of influence on CYP enzymes, the dosage form, and food interactions. Studies on the interaction between P-CABs and antibiotics used to treat <jats:italic>H. pylori<\/jats:italic> infections, such as metronidazole, tetracycline, levofloxacin, or rifabutin, as well as non-vitamin K antagonist oral anticoagulants are lacking, and further research is needed.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fphar.2025.1580969","type":"journal-article","created":{"date-parts":[[2025,7,8]],"date-time":"2025-07-08T09:02:58Z","timestamp":1751965378000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":16,"title":["Clinical pharmacokinetics of potassium competitive acid blockers: a systematic review and meta-analysis"],"prefix":"10.3389","volume":"16","author":[{"given":"Jiaqi","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jongsung","family":"Hahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,7,8]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1080\/00325481.2024.2320081","article-title":"Potassium-competitive acid blockers: rethinking acid suppression for gastroesophageal reflux disease and Helicobacter pylori","volume":"136","author":"Antequera","year":"2024","journal-title":"Postgrad. Med."},{"key":"B2","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1080\/17425255.2022.2098107","article-title":"An update on drug-drug interactions associated with proton pump inhibitors","volume":"18","author":"Ben","year":"2022","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1016\/j.clinthera.2012.07.004","article-title":"Bioavailability and tolerability of combination treatment with revaprazan 200 mg + itopride 150 mg: a randomized crossover study in healthy male Korean volunteers","volume":"34","author":"Choi","year":"2012","journal-title":"Clin. Ther."},{"key":"B4","doi-asserted-by":"publisher","first-page":"6529","DOI":"10.3748\/wjg.v19.i39.6529","article-title":"Proton pump inhibitor resistance, the real challenge in gastro-esophageal reflux disease","volume":"19","author":"Cicala","year":"2013","journal-title":"World J. Gastroenterol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1515\/dmdi-2014-0034","article-title":"Pharmacogenetics of drug metabolizing enzymes in the United Kingdom population: review of current knowledge and comparison with selected European populations","volume":"30","author":"Daly","year":"2015","journal-title":"Drug Metabolism Personalized Ther."},{"key":"B6","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/0195-6701(91)90215-t","article-title":"The pharmacokinetics of clarithromycin and its 14-OH metabolite","volume":"19","author":"Davey","year":"1991","journal-title":"J. Hosp. Infect."},{"key":"B7","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1007\/s40261-024-01359-x","article-title":"Pharmacokinetic interactions between tegoprazan and the combination of clarithromycin, amoxicillin and bismuth in healthy Chinese subjects: an open-label, single-center, multiple-dosage, self-controlled, phase I trial","volume":"44","author":"Du","year":"2024","journal-title":"Clin. Drug Investig."},{"key":"B8","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1007\/s40262-015-0326-7","article-title":"The first-in-class potassium-competitive acid blocker, vonoprazan fumarate: pharmacokinetic and pharmacodynamic considerations","volume":"55","author":"Echizen","year":"2016","journal-title":"Clin. Pharmacokinet."},{"key":"B9","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1136\/gutjnl-2016-313589","article-title":"Global prevalence of, and risk factors for, gastro-oesophageal reflux symptoms: a meta-analysis","volume":"67","author":"Eusebi","year":"2018","journal-title":"Gut"},{"key":"B68","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1097\/MCG.0000000000002052","article-title":"Efficacy and safety of potassium-competitive acid blockers versus proton pump inhibitors in treating erosive esophagitis: a meta-analysis based on randomized controlled trials","volume":"58","author":"Fang","year":"2024","journal-title":"J. Clin. Gastroenterol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"1454","DOI":"10.1111\/bcp.13914","article-title":"Effects of proton pump inhibitors, esomeprazole and vonoprazan, on the disposition of proguanil, a CYP2C19 substrate, in healthy volunteers","volume":"85","author":"Funakoshi","year":"2019","journal-title":"Br. J. Clin. Pharmacol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1515\/dmpt-2016-0024","article-title":"Genetic polymorphisms of cytochrome P450 enzymes: CYP2C9, CYP2C19, CYP2D6, CYP3A4, and CYP3A5 in the Croatian population","volume":"32","author":"Ganoci","year":"2017","journal-title":"Drug Metab. Pers. Ther."},{"key":"B13","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1002\/jcph.1805","article-title":"Pharmacokinetics and pharmacodynamics of tegoprazan coadministered with amoxicillin and clarithromycin in healthy subjects","volume":"61","author":"Ghim","year":"2021","journal-title":"J. Clin. Pharmacol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1002\/mnfr.200700081","article-title":"Gauging the clinical significance of P-glycoprotein-mediated herb-drug interactions: comparative effects of St. John's wort, Echinacea, clarithromycin, and rifampin on digoxin pharmacokinetics","volume":"52","author":"Gurley","year":"2008","journal-title":"Mol. Nutr. Food Res."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1016\/j.clinthera.2021.06.007","article-title":"Effect of food on the pharmacokinetics and pharmacodynamics of a single oral dose of tegoprazan","volume":"43","author":"Han","year":"2021","journal-title":"Clin. Ther."},{"key":"B16","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/1471-2288-5-13","article-title":"Estimating the mean and variance from the median, range, and the size of a sample","volume":"5","author":"Hozo","year":"2005","journal-title":"BMC Med. Res. Methodol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1111\/bcp.14934","article-title":"Evaluation of safety and pharmacokinetics of bismuth-containing quadruple therapy with either vonoprazan or lansoprazole for Helicobacter pylori eradication","volume":"88","author":"Huh","year":"2022","journal-title":"Br. J. Clin. Pharmacol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1111\/apt.17406","article-title":"Randomised clinical trial: safety, tolerability, pharmacodynamics and pharmacokinetics of zastaprazan (JP-1366), a novel potassium-competitive acid blocker, in healthy subjects","volume":"57","author":"Hwang","year":"2023","journal-title":"Aliment. Pharmacol. Ther."},{"key":"B19","doi-asserted-by":"publisher","first-page":"1648","DOI":"10.1111\/apt.16131","article-title":"Pharmacodynamics and pharmacokinetics of DWP14012 (fexuprazan) in healthy subjects with different ethnicities","volume":"52","author":"Hwang","year":"2020","journal-title":"Alimentary Pharmacol. Ther."},{"key":"B20","doi-asserted-by":"publisher","first-page":"80","DOI":"10.12793\/tcp.2019.27.2.80","article-title":"Comparison of pharmacokinetic characteristics of two tegoprazan (CJ-12420) formulations in healthy male subjects","volume":"27","author":"Hwang","year":"2019","journal-title":"Transl. Clin. Pharmacol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"754849","DOI":"10.3389\/fphar.2021.754849","article-title":"Co-administration of vonoprazan, not tegoprazan, affects the pharmacokinetics of atorvastatin in healthy male subjects","volume":"12","author":"Hwang","year":"2021","journal-title":"Front. Pharmacol."},{"key":"B22","article-title":"Ethnic Factors in the Acceptability of Foreign Clinical Data (ICH E5)","year":"1998"},{"key":"B23","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1007\/s40261-016-0488-6","article-title":"Effect of multiple oral doses of the potent CYP3A4 inhibitor clarithromycin on the pharmacokinetics of a single oral dose of vonoprazan: a phase I, open-label, sequential design study","volume":"37","author":"Jenkins","year":"2017","journal-title":"Clin. Drug Investig."},{"key":"B24","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1111\/apt.13121","article-title":"Randomised clinical trial: safety, tolerability, pharmacokinetics and pharmacodynamics of repeated doses of TAK-438 (vonoprazan), a novel potassium-competitive acid blocker, in healthy male subjects","volume":"41","author":"Jenkins","year":"2015","journal-title":"Aliment. Pharmacol. Ther."},{"key":"B25","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1016\/j.clinthera.2021.01.026","article-title":"Pharmacokinetic interactions between tegoprazan and metronidazole\/tetracycline\/bismuth and safety assessment in healthy Korean male subjects","volume":"43","author":"Jeon","year":"2021","journal-title":"Clin. Ther."},{"key":"B26","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1124\/dmd.106.013581","article-title":"Identification and functional characterization of genetic variants of human organic cation transporters in a Korean population","volume":"35","author":"Kang","year":"2007","journal-title":"Drug Metab. Dispos."},{"key":"B27","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.3748\/wjg.v30.i9.1213","article-title":"Treatment of Helicobacter pylori with potassium competitive acid blockers: a systematic review and meta-analysis","volume":"30","author":"Kanu","year":"2024","journal-title":"World J. Gastroenterol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"27","DOI":"10.14309\/ajg.0000000000001538","article-title":"ACG clinical guideline for the diagnosis and management of gastroesophageal reflux disease","volume":"117","author":"Katz","year":"2022","journal-title":"Am. J. Gastroenterol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1111\/j.1365-2036.2006.02944.x","article-title":"Review article: acid-related disease--what are the unmet clinical needs?","volume":"23","author":"Katz","year":"2006","journal-title":"Aliment. Pharmacol. Ther."},{"key":"B30","doi-asserted-by":"publisher","first-page":"98","DOI":"10.12793\/tcp.2024.32.e9","article-title":"Enhancing drug administration flexibility: evaluation of pharmacokinetic properties of tegoprazan orally disintegrating tablet (ODT) administered via nasogastric tube or oral dosing","volume":"32","author":"Kim","year":"2024","journal-title":"Transl. Clin. Pharmacol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1080\/00498254.2016.1182667","article-title":"Disposition and metabolism of TAK-438 (vonoprazan fumarate), a novel potassium-competitive acid blocker, in rats and dogs","volume":"47","author":"Kogame","year":"2017","journal-title":"Xenobiotica"},{"key":"B32","doi-asserted-by":"publisher","first-page":"410","DOI":"10.5414\/CP204378","article-title":"Evaluation of the comparative pharmacokinetic properties of a new orally disintegrating tablet of tegoprazan in healthy Korean subjects","volume":"61","author":"Lee","year":"2023","journal-title":"Int. J. Clin. Pharmacol. Ther."},{"key":"B33","doi-asserted-by":"publisher","first-page":"356","DOI":"10.47102\/annals-acadmedsg.v40n8p356","article-title":"Inter-ethnic differences--how important is it in cancer treatment?","volume":"40","author":"Ling","year":"2011","journal-title":"Ann. Acad. Med. Singap"},{"key":"B34","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1016\/s0140-6736(84)91816-6","article-title":"Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration","volume":"1","author":"Marshall","year":"1984","journal-title":"Lancet"},{"key":"B35","doi-asserted-by":"publisher","first-page":"1600","DOI":"10.1248\/bpb.b20-00361","article-title":"Effects of concomitant administration of vonoprazan fumarate on the tacrolimus blood concentration in kidney transplant recipients","volume":"43","author":"Mei","year":"2020","journal-title":"Biol. Pharm. Bull."},{"key":"B36","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1002\/cpdd.1276","article-title":"Pharmacokinetics, safety, and tolerability of vonoprazan- or esomeprazole-based bismuth-containing quadruple therapy: a phase 1, double-blind, parallel-group study in adults with Helicobacter pylori infection in China","volume":"12","author":"Miao","year":"2023","journal-title":"Clin. Pharmacol. Drug Dev."},{"key":"B37","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1016\/j.clinthera.2022.06.002","article-title":"Pharmacokinetic interactions between tegoprazan and naproxen, aceclofenac, and celecoxib in healthy Korean male subjects","volume":"44","author":"Moon","year":"2022","journal-title":"Clin. Ther."},{"key":"B38","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1002\/cpdd.1009","article-title":"The effect of food on the pharmacokinetics of the potassium-competitive acid blocker vonoprazan","volume":"11","author":"Mulford","year":"2022","journal-title":"Clin. Pharmacol. Drug Dev."},{"key":"B39","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1002\/psp4.12939","article-title":"Tiered approach to evaluate the CYP3A victim and perpetrator drug\u2013drug interaction potential for vonoprazan using PBPK modeling and clinical data to inform labeling","volume":"12","author":"Mulford","year":"2023","journal-title":"CPT Pharmacometrics Syst. Pharmacol."},{"key":"B40","doi-asserted-by":"publisher","first-page":"143","DOI":"10.2131\/jts.41.143","article-title":"Effect of penicillin-based antibiotics, amoxicillin, ampicillin, and piperacillin, on drug-metabolizing activities of human hepatic cytochromes P450","volume":"41","author":"Niwa","year":"2016","journal-title":"J. Toxicol. Sci."},{"key":"B41","doi-asserted-by":"publisher","first-page":"549","DOI":"10.3390\/pharmaceutics15020549","article-title":"Pharmacodynamic and pharmacokinetic drug interactions between fexuprazan, a novel potassium-competitive inhibitor, and aspirin, in healthy subjects","volume":"15","author":"Oh","year":"2023","journal-title":"Pharmaceutics"},{"key":"B42","doi-asserted-by":"publisher","first-page":"114","DOI":"10.12793\/tcp.2023.31.e11","article-title":"Evaluation of pharmacokinetic drug-drug interaction between tegoprazan and clarithromycin in healthy subjects","volume":"31","author":"Oh","year":"2023","journal-title":"Transl. Clin. Pharmacol."},{"key":"B43","doi-asserted-by":"publisher","first-page":"2877","DOI":"10.1111\/bcp.15784","article-title":"Pharmacokinetic and pharmacodynamic exploration of various combinations of tegoprazan immediate and delayed-release formulations","volume":"89","author":"Park","year":"2023","journal-title":"Br. J. Clin. Pharmacol."},{"key":"B44","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1053\/j.gastro.2024.06.038","article-title":"AGA clinical practice update on integrating potassium-competitive acid blockers into clinical practice: expert review","volume":"167","author":"Patel","year":"2024","journal-title":"Gastroenterology"},{"key":"B45","doi-asserted-by":"publisher","first-page":"e94","DOI":"10.1038\/ctg.2015.18","article-title":"Safety, tolerability, pharmacokinetics, and pharmacodynamics of single rising TAK-438 (vonoprazan) doses in healthy male Japanese\/non-Japanese subjects","volume":"6","author":"Sakurai","year":"2015","journal-title":"Clin. Transl. Gastroenterol."},{"key":"B46","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1007\/s40261-016-0455-2","article-title":"Pharmacokinetic drug\u2013drug interactions between vonoprazan and low-dose aspirin or nonsteroidal anti-inflammatory drugs: a phase 2, open-label, study in healthy Japanese men","volume":"37","author":"Sakurai","year":"2017","journal-title":"Clin. Drug Investig."},{"key":"B47","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1007\/s12325-016-0374-x","article-title":"Pharmacokinetics and safety of triple therapy with vonoprazan, amoxicillin, and clarithromycin or metronidazole: a phase 1, open-label, randomized, crossover study","volume":"33","author":"Sakurai","year":"2016","journal-title":"Adv. Ther."},{"key":"B48","doi-asserted-by":"publisher","first-page":"259","DOI":"10.5056\/jnm24024","article-title":"Treatment response with potassium-competitive acid blockers based on clinical phenotypes of gastroesophageal reflux disease: a systematic literature review and meta-analysis","volume":"30","author":"Seo","year":"2024","journal-title":"J. Neurogastroenterol. Motil."},{"key":"B49","doi-asserted-by":"publisher","first-page":"25","DOI":"10.5056\/jnm.2013.19.1.25","article-title":"Pharmacokinetics and pharmacodynamics of the proton pump inhibitors","volume":"19","author":"Shin","year":"2013","journal-title":"J. Neurogastroenterol. Motil."},{"key":"B50","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.3390\/ph16081141","article-title":"A comparative pharmacokinetic study of fexuprazan 10 mg: demonstrating bioequivalence with the reference formulation and evaluating steady state","volume":"16","author":"Shin","year":"2023","journal-title":"Pharmaceuticals"},{"key":"B51","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1111\/apt.14818","article-title":"Safety, tolerability, pharmacodynamics and pharmacokinetics of DWP14012, a novel potassium-competitive acid blocker, in healthy male subjects","volume":"48","author":"Sunwoo","year":"2018","journal-title":"Alimentary Pharmacol. Ther."},{"key":"B52","doi-asserted-by":"publisher","first-page":"1900","DOI":"10.1111\/j.1572-0241.2006.00630.x","article-title":"The Montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensus","volume":"101","author":"Vakil","year":"2006","journal-title":"Am. J. Gastroenterol."},{"key":"B53","doi-asserted-by":"publisher","first-page":"9852518","DOI":"10.34133\/2022\/9852518","article-title":"Distribution- and metabolism-based drug discovery: a potassium-competitive acid blocker as a proof of concept","volume":"2022","author":"Wang","year":"2022","journal-title":"Res. (Wash D C)"},{"key":"B54","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.14309\/ctg.0000000000000754","article-title":"Efficacy and safety of potassium-competitive acid blockers vs proton pump inhibitors for peptic ulcer disease or postprocedural artificial ulcers: a systematic review and meta-analysis","volume":"15","author":"Wang","year":"2024","journal-title":"Clin. Transl. Gastroenterology"},{"key":"B55","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1111\/j.1365-2125.1991.tb05594.x","article-title":"The activation of the biguanide antimalarial proguanil co-segregates with the mephenytoin oxidation polymorphism--a panel study","volume":"31","author":"Ward","year":"1991","journal-title":"Br. J. Clin. Pharmacol."},{"key":"B56","doi-asserted-by":"publisher","first-page":"100407","DOI":"10.1016\/j.dmpk.2021.100407","article-title":"Blood concentrations of tacrolimus upon conversion from rabeprazole to vonoprazan in renal transplant recipients: correlation with cytochrome P450 gene polymorphisms","volume":"40","author":"Watari","year":"2021","journal-title":"Drug Metabolism Pharmacokinet."},{"key":"B57","doi-asserted-by":"publisher","first-page":"e13798","DOI":"10.1111\/cts.13798","article-title":"Pharmacokinetic interactions between fexuprazan, a potassium-competitive acid blocker, and nonsteroidal anti-inflammatory drugs in healthy males","volume":"17","author":"Won","year":"2024","journal-title":"Clin. Transl. Sci."},{"key":"B58","doi-asserted-by":"crossref","first-page":"S151","DOI":"10.1016\/S0016-5085(17)30828-4","article-title":"Potassium-competitive acid blocker versus proton pump inhibitor as first-line triple therapy for helicobacter pylori eradication: a systematic review and meta-analysis","volume":"152","author":"Yamade","year":"2017","journal-title":"Gastroenterology"},{"key":"B59","first-page":"124","article-title":"Concentration of clarithromycin and 14-R-hydroxy-clarithromycin in plasma of patients with Mycobacterium avium complex infection, before and after the addition of rifampicin","volume":"57","author":"Yamamoto","year":"2004","journal-title":"Jpn. J. Antibiot."},{"key":"B60","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1080\/00498254.2016.1203505","article-title":"In vitro metabolism of TAK-438, vonoprazan fumarate, a novel potassium-competitive acid blocker","volume":"47","author":"Yamasaki","year":"2017","journal-title":"Xenobiotica"},{"key":"B61","doi-asserted-by":"publisher","first-page":"40","DOI":"10.12793\/tcp.2023.31.e3","article-title":"Size-reduced fexuprazan 20 mg demonstrated the optimal bioavailability and bioequivalence with the reference formulation","volume":"31","author":"Yang","year":"2023","journal-title":"Transl. Clin. Pharmacol."},{"key":"B62","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1007\/s40262-023-01228-4","article-title":"Evaluation of CYP2C19-mediated pharmacokinetic drug interaction of tegoprazan, compared with vonoprazan or esomeprazole","volume":"62","author":"Yang","year":"2023","journal-title":"Clin. Pharmacokinet."},{"key":"B63","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1038\/clpt.2008.141","article-title":"The role of ethnicity in variability in response to drugs: focus on clinical pharmacology studies","volume":"84","author":"Yasuda","year":"2008","journal-title":"Clin. Pharmacol. Ther."},{"key":"B64","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.1007\/s10637-022-01304-9","article-title":"Effects of CYP3A4\/5 and ABC transporter polymorphisms on osimertinib plasma concentrations in Japanese patients with non-small cell lung cancer","volume":"40","author":"Yokota","year":"2022","journal-title":"Invest. New Drugs"},{"key":"B65","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1111\/cts.12958","article-title":"Effect of meal timing on pharmacokinetics and pharmacodynamics of tegoprazan in healthy male volunteers","volume":"14","author":"Yoon","year":"2021","journal-title":"Clin. Transl. Sci."},{"key":"B66","doi-asserted-by":"publisher","first-page":"106578","DOI":"10.1016\/j.ejps.2023.106578","article-title":"Keverprazan, a novel potassium-competitive acid blocker: single ascending dose safety, tolerability, pharmacokinetics, pharmacodynamics and food effect in healthy subjects","volume":"190","author":"Zhou","year":"2023","journal-title":"Eur. J. Pharm. Sci."},{"key":"B67","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1002\/phar.2899","article-title":"Acid-suppressive drugs: a systematic review and network meta-analysis of their nocturnal acid-inhibitory effect","volume":"44","author":"Zou","year":"2024","journal-title":"Pharmacotherapy"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1580969\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,8]],"date-time":"2025-07-08T09:02:59Z","timestamp":1751965379000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1580969\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,8]]},"references-count":67,"alternative-id":["10.3389\/fphar.2025.1580969"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2025.1580969","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,8]]},"article-number":"1580969"}}